This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Its Topical Use in Aural and Pharyngeal Infections

JAMES E. COYLE, M.D.; KATHARINE COLLINS, B.A.; WALTER J. NUNGESTER, M.D.

Arch Otolaryngol. 1949;50(3):284-289.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

RECENT advances in the treatment of infectious diseases, made possible by the discovery of bacteriostatic agents, have inspired medical investigators to study an ever increasing number of chemotherapeutic and antibiotic substances. Many different compounds have been isolated and tested in the laboratory and used clinically, but only a few of them have proved to be of definite value. The great majority have been unsatisfactory either because of their excessive toxicity or because of their failure to act specifically on the organism for which an inhibiting substance was being sought.

It is our purpose in this paper to report additional studies with a relatively new antibiotic agent, bacitracin. Bacitracin was first reported by Johnson, Anker and Meleney,¹ in 1945. It had been produced by a strain of Bacillus subtilis recovered from a mixture of organisms contaminating the débrided tissue removed from a compound tibial fracture. After having investigated the properties . . . [Full Text PDF of this Article]

Author Affiliations
ANN ARBOR, MICH.

From the Departments of Otolaryngology and Bacteriology, University of Michigan.

Footnotes
This work was aided by a grant from the Upjohn Company of Kalamazoo, Mich.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?